// App-Quantinova.ai

: Efficacy and Safety of Rivaroxaban Thromboprophylaxis by Khorana Score Category: A Subgroup Analysis of CASSINI

Researchers

Presenter

  • A. Khorana

Principal Investigators

  • N. Kuderer

  • M.G. McNamara

  • T. Wun

  • D.A. Garcia

  • U. Vijapurkar

  • S. Kaul

  • P. Wildgoose

  • G. Lyman

Medical Centers

  • Cleveland Clinic, Hematology Oncology, Cleveland, United States

  • Advanced Cancer Research Group, University of Washington School of Medicine, Seattle, United States

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA

  • University of Washington School of Medicine, Seattle, Washington, United States

  • Janssen Research & Development, LLC, United States

  • Janssen Scientific Affairs, LLC, Titusville, New Jersey, United States

  • Advanced Cancer Research Group, University of Washington School of Medicine, Seattle, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved